The deubiquitinating enzyme USP11 regulates breast cancer progression by stabilizing PGAM5

• Published in: Breast cancer research : BCR 2024-09, Vol.26 (1), p.135-13, Article 135
• Main Authors: Zhang, Nannan, Wang, Quhui, Lu, Yunpeng, Wang, Feiran, He, Zhixian
• Format: Article
• Language: English
• Subjects: Animals; Apoptosis; Apoptosis - genetics; Breast cancer; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Cell Line, Tumor; Cell Proliferation; Development and progression; Disease Progression; Female; Ferroptosis; Gene Expression Regulation, Neoplastic; Glycolytic enzymes; Health aspects; Humans; Mice; Mitochondrial Proteins; PGAM5; Phosphoprotein Phosphatases - genetics; Phosphoprotein Phosphatases - metabolism; Physiological aspects; Protein Stability; Thiolester Hydrolases - genetics; Thiolester Hydrolases - metabolism; Ubiquitin-proteasome system; Ubiquitination; USP11
• ISSN: 1465-542X; 1465-5411; 1465-542X
• DOI: 10.1186/s13058-024-01892-9

Breast cancer is common worldwide. Phosphoglycerate mutase 5 (PGAM5) belongs to the phosphoglycerate mutase family and plays an important role in many cancers. However, research on its role in breast cancer remains unclear. The present investigation highlights the significant expression of PGAM5 in breast cancer and its essential role in cell proliferation, invasion, apoptosis and the regulation of ferroptosis in breast cancer cells. Overexpression or knockdown of ubiquitin-specific protease 11 (USP11) promotes or inhibits the growth and metastasis of breast cancer cells, respectively, in vitro and in vivo. Mechanistically, USP11 stabilizes PGAM5 via de-ubiquitination, protecting it from proteasome-mediated degradation. In addition, the USP11/PGAM5 complex promotes breast cancer progression by activating iron death-related proteins, indicating that the synergy between USP11 and PGAM5 may serve as a predictor of disease outcome and provide a new treatment strategy for breast cancer.